COMMUNIQUÉS West-GlobeNewswire

Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible [...]
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026
Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full [...]
SafeSpace Global Corporation Transitions from Pre-Revenue to Active Revenue Generation with Eight Contracted Senior Living Facility Installations
23/02/2026
Company Begins Recurring Monthly Revenue Stream in February 2026 through Deployment of AI-powered, Privacy-Aware Technology that Replaces Wearables and Loud Alarms with Proactive and Dignified Resident Safety KNOXVILLE [...]
Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana
23/02/2026
Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assets Expansion planned to enable Solana Company to [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
23/02/2026
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 study to evaluate [...]
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
23/02/2026
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
23/02/2026
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced [...]
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
23/02/2026
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS ), a clinical- [...]
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
23/02/2026
Dr. Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, brings leadership experience spanning approximately 50 regulatory approvals and over $100 billion in [...]
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
23/02/2026
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 [...]
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” [...]
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
23/02/2026
DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and [...]
J-Star Signs Exclusive Distribution Agreement with PSSB
23/02/2026
TAICHUNG CITY, Taiwan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse [...]
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
23/02/2026
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- [...]
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]

Pages